Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo Controlled, Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive, HER-2 Negative, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole

Trial Profile

A Randomized, Double-blind, Placebo Controlled, Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive, HER-2 Negative, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole

Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2019

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms BOLERO-5
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 22 Oct 2018 Planned End Date changed from 31 Mar 2021 to 3 Sep 2021.
    • 22 Oct 2018 Planned primary completion date changed from 28 Jun 2019 to 3 Dec 2019.
    • 30 Sep 2018 Planned End Date changed from 2 Sep 2021 to 31 Mar 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top